{
    "clinical_study": {
        "@rank": "19831", 
        "arm_group": {
            "arm_group_label": "Basic Science (deuterated phenanthrene tetraol)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive deuterated phenanthrene tetraol PO. Urine samples are collected for laboratory studies for 6 hours after dosing."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies deuterated phenanthrene tetraol in smokers who are at high risk\n      for lung cancer. Studying samples of urine in the laboratory from smokers who are at high\n      risk for lung cancer may help doctors learn more about biomarkers related to cancer."
        }, 
        "brief_title": "Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lung Cancer", 
            "Squamous Lung Dysplasia", 
            "Tobacco Use Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lung Neoplasms", 
                "Tobacco Use Disorder"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the relationship between urinary deuterated ([D10]) phenanthrene tetraol\n      (PheT) level, PheT:phenanthrols (HOPhe) ratio, and the presence of bronchoepithelial\n      metaplasia and/or dysplasia in smokers who have undergone screening bronchoscopy at Roswell\n      Park Cancer Institute (RPCI).\n\n      OUTLINE:\n\n      Patients receive deuterated phenanthrene tetraol orally (PO). Urine samples are collected\n      for laboratory studies for 6 hours after dosing."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Enrolled in the High Risk Lung Cancer (HRLC) Screening Program\n\n          -  Eligible for bronchoscopy or have undergone screening bronchoscopy in the past\n\n          -  Current smoker of at least 10 cigarettes daily\n\n          -  Able to provide written consent indicating an understanding of the investigational\n             nature of the study\n\n          -  Willing to take [D10]phenanthrene in water with 20% ethanol\n\n        Exclusion Criteria:\n\n          -  Previous aerodigestive tract cancer\n\n          -  Currently attempting to cut down or quit smoking\n\n          -  Major medical co-morbidities, for example, renal dysfunction, heart failure, and\n             diabetes, to be adjudicated by study physicians\n\n          -  Pregnant women, women intending to become pregnant, or women who are breastfeeding\n\n          -  Former or recovering alcoholics\n\n          -  Those needing to take medications such as metronidazole, chlorpromazine, Antabuse or\n             benzodiazepines within 7 days of the deuterated phenanthrene dosing, as they could\n             potentially interact with ethanol; ineligibility based on use of other medications is\n             at the discretion of the study physicians"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "350", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01673711", 
            "org_study_id": "2011NTUC092", 
            "secondary_id": "NCI-2012-01148"
        }, 
        "intervention": [
            {
                "arm_group_label": "Basic Science (deuterated phenanthrene tetraol)", 
                "description": "Given PO", 
                "intervention_name": "deuterated phenanthrene tetraol", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "[D10] phenanthrene", 
                    "phenanthrene-D10"
                ]
            }, 
            {
                "arm_group_label": "Basic Science (deuterated phenanthrene tetraol)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }, 
            {
                "arm_group_label": "Basic Science (deuterated phenanthrene tetraol)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "contact": {
                "email": "AKSRPCI@roswellpark.org", 
                "last_name": "Roswell Park", 
                "phone": "877-275-7724"
            }, 
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14263"
                }, 
                "name": "Roswell Park Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Alex A. Adjei", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Correlation of [D10] Phenanthrene Metabolism With Bronchoepitheial Dysplasia and Metaplasia in Smokers at High Risk for Lung Cancer", 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "Stephen S Hecht, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "A multiple regression analysis will be performed including explanatory variables such as lesion status, presence/absence of chronic obstructive pulmonary disease (COPD) or asbestos, duration of smoking, smoking intensity, age, and gender.", 
                "measure": "Urinary deuterated phenanthrene tetraol level", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 hours"
            }, 
            {
                "description": "A multiple regression analysis will be performed including explanatory variables such as lesion status, presence/absence of COPD or asbestos, duration of smoking, smoking intensity, age, and gender.", 
                "measure": "PheT:HOPhe ratio", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 hours"
            }, 
            {
                "description": "A multiple regression analysis will be performed including explanatory variables such as lesion status, presence/absence of COPD or asbestos, duration of smoking, smoking intensity, age, and gender.", 
                "measure": "Correlation of deuterated phenanthrene tetraol level and PheT:HOPhe ratio with the presence of bronchoepithelial metaplasia and/or dysplasia", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01673711"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Masonic Cancer Center, University of Minnesota", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Masonic Cancer Center, University of Minnesota", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}